Insulet publishes investor presentation outlining Omnipod growth strategy and product pipeline
Reuters2026/08/05 11:26- Insulet outlined growth plans around Omnipod 5 expansion, a next-generation Omnipod 6 platform, and a fully closed-loop system for type 2 diabetes.
- Reported 2025 revenue of USD 2.7 billion, more than 600,000 active customers, and presence in 26 global markets.
- Targets U.S. type 1 diabetes penetration of 50%-55% by 2028 from about 40% today; targets U.S. type 2 diabetes penetration of 10%-15% from about 5%.
- Pipeline milestones include Omnipod 6 clinical study results with a 510(k) filing, then launch; type 2 fully closed-loop pivotal study start, 510(k) filing, then launch.
- Highlighted 2021-2025 financial trajectory, including adjusted operating margin rising to 17.6% and free cash flow of USD 378 million in 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan optimistic forecast: Strengthening yen may ease pressure on Japanese bonds, Japanese AI and semiconductor sectors expected to recover ahead of schedule
JPMorgan believes that a stronger yen is likely to ease the upward pressure on Japanese government bond yields, thereby boosting an early recovery for AI and semiconductor stocks listed in Tokyo.
Hunter Biden Lays Out LAPTOP Airdrop Plan Before Base Debut
Nihon Dempa Kogyo Expected to Benefit From Growing Data-Center Demand -- Market Talk
The $35 billion acquisition of Teck Resources initiates a revaluation of valuations; Anglo American (AAUKF.US) receives an "Outperform" rating from Scotiabank.
Scotiabank has covered Anglo American (AAUKF.US) for the first time, assigning it an “Outperform” rating with a target price of £52 per share.
Crypto prices
More
